The risk of corruption in public pharmaceutical procurement: how anti-corruption, transparency and accountability measures may reduce this risk
Background: The goal of the public procurement of pharmaceuticals is to purchase sufficient quantities of high-quality pharmaceuticals at cost-effective prices for a given population. This goal can be undercut if corruption infiltrates the procurement process. Good procurement practices can help mit...
Saved in:
Main Authors: | Jillian Clare Kohler (Author), Deirdre Dimancesco (Author) |
---|---|
Format: | Book |
Published: |
Taylor & Francis Group,
2020-02-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Corruption risks in health procurement during the COVID-19 pandemic and anti-corruption, transparency and accountability (ACTA) mechanisms to reduce these risks: a rapid review
by: Kari A. Griffore, et al.
Published: (2023) -
The Global Fund: why anti-corruption, transparency and accountability matter
by: Zhihao Chang, et al.
Published: (2021) -
An interdisciplinary review of digital technologies to facilitate anti-corruption, transparency and accountability in medicines procurement
by: Tim K. Mackey, et al.
Published: (2020) -
Transparency and corruption risk in pharmaceutical procurement practices at public health facilities in Northeast Ethiopia: a multi-facility study
by: Ewunetie Mekashaw Bayked, et al.
Published: (2024) -
Can a multistakeholder initiative improve transparency and accountability in the pharmaceutical sector? Evidence from the Medicines Transparency Alliance
by: Taryn Vian, PhD, et al.
Published: (2017)